Management of immune-related adverse events resulting from immune checkpoint blockade

References

• Thompson JA. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Cancer Netw JNCCN. 2018;16:594–596.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1714–1768.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:iv119–iv142.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Belum VR, Benhuri B, Postow MA, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer Oxf (Engl 1990). 2016;60:12–25.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. [Internet]. 2015;373:23–34.
   PubMed Web of Science ®Google Scholar
• Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152:45–51.
   PubMed Web of Science ®Google Scholar
• Horvat TZ, Adel NG, Dang T-O, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:3193–3198.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Marthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016;10:395–401.
   PubMed Web of Science ®Google Scholar
• Baroudjian B, Lourenco N, Pagès C, et al. Anti-PD1-induced collagenous colitis in a melanoma patient. Melanoma Res. 2016;26:308–311.
   PubMed Web of Science ®Google Scholar
• Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:103–110.
   PubMed Web of Science ®Google Scholar
• Pagès C, Gornet JM, Monsel G, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res. 2013;23:227–230.
   PubMed Web of Science ®Google Scholar
• Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother CII. 2017;66:581–592.
   PubMed Web of Science ®Google Scholar
• Arriola E, Wheater M, Karydis I, et al. Infliximab for ipilimumab-related colitis-letter. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:5642–5643.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2018;29:250–255.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst. 2017;109.
   PubMedGoogle Scholar
• Michot J-M, Ragou P, Carbonnel F, et al. Significance of immune-related lipase increase induced by antiprogrammed death-1 or death ligand-1 antibodies: a brief communication. J Immunother (Hagerstown Md 1997). 2018;41:84–85.
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21:1712–1717.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
   PubMed Web of Science ®Google Scholar
• Zhang X, Ran Y, Wang K, et al. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther. 2016 Mar 30;10:3153–3161.
   PubMed Web of Science ®Google Scholar
• Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075–1084.
   PubMed Web of Science ®Google Scholar
• Wu Z, Lai L, Li M, et al. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: a case report. Medicine (Baltimore). 2017;96:e9431.
   PubMed Web of Science ®Google Scholar
• De Martin E, Michot J-M, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–1190.
   PubMed Web of Science ®Google Scholar
• Gauci M-L, Baroudjian B, Zeboulon C, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J Hepatol. 2018;69:548–550. On line first.
   PubMed Web of Science ®Google Scholar
• Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473–486.
   PubMed Web of Science ®Google Scholar
• Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691–2697.
   PubMed Web of Science ®Google Scholar
• Imafuku K, Yoshino K, Yamaguchi K, et al. Successful treatment of sudden hepatitis induced by long-term nivolumab administration. Case Rep Oncol. 2017;10:368–371.
   PubMed Web of Science ®Google Scholar
• Alessandrino F, Tirumani SH, Krajewski KM, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017;72:521–533.
   PubMed Web of Science ®Google Scholar
• Kim KW, Ramaiya NH, Krajewski KM, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs. 2013;31:1071–1077.
   PubMed Web of Science ®Google Scholar
• Mekki A, Dercle L, Lichtenstein P, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer Oxf (Engl 1990). 2018;96:91–104.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Vitale G, D’Errico A, et al. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:671–672.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Tanizaki J, Tanaka K, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs. 2017;35:529–536.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer Oxf Engl 1990. 2016;54:139–148.
   PubMed Web of Science ®Google Scholar
• Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95.
   PubMed Web of Science ®Google Scholar
• Cheng R, Cooper A, Kench J, et al. Ipilimumab‐induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015;30:657–666.
   PubMed Web of Science ®Google Scholar
• Everett J, Srivastava A, Misdraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol. 2017;41:134–137.
   PubMed Web of Science ®Google Scholar
• Simonelli M, Di Tommaso L, Baretti M, et al. Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy. 2016;8:1363–1369.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Nishida T, Higaki Y, et al. Nivolumab induces sustained liver injury in a patient with malignant melanoma. Intern Med Tokyo Jpn. 2018;57:1789–1792.
   Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287.
   PubMed Web of Science ®Google Scholar
• Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17:943–955.
   PubMed Web of Science ®Google Scholar
• Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013;23:47–54.
   PubMed Web of Science ®Google Scholar
• Kanz BA, Pollack MH, Johnpulle R, et al. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016;4:60.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet Lond Engl. 2017;389:2492–2502.
   PubMed Web of Science ®Google Scholar
• Alkharabsheh O, Kannarkatt P, Kannarkatt J, et al. An overview of the toxicities of checkpoint inhibitors in older patients with cancer. J Geriatr Oncol. 2018;9:451–458.
   PubMed Web of Science ®Google Scholar
• Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
   PubMed Web of Science ®Google Scholar
• Chmiel KD, Suan D, Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:e237–e240.
   PubMed Web of Science ®Google Scholar
• Ziemer M, Koukoulioti E, Beyer S, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66:657–659.
   PubMed Web of Science ®Google Scholar
• Del Castillo M, Romero FA, Argüello E, et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:1490–1493.
   PubMed Web of Science ®Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:559–574.
   PubMed Web of Science ®Google Scholar
• Byun DJ, Wolchok JD, Rosenberg LM, et al. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017;13:195–207.
   PubMed Web of Science ®Google Scholar
• Gauci M-L, Boudou P, Baroudjian B, et al. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. Cancer Immunol Immunother CII. 2018;67:1197–1208.
   PubMed Web of Science ®Google Scholar
• Maker AV, Yang JC, Sherry RM, et al. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (Hagerstown Md 1997). 2006;29:455–463.
   PubMed Web of Science ®Google Scholar
• Lupu J, Pages C, Laly P, et al. Transient pituitary ACTH-dependent cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Res. 2017;27:649–652.
   PubMed Web of Science ®Google Scholar
• Weber JS, Postow M, Lao CD, et al. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–1240.
   PubMed Web of Science ®Google Scholar
• Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017;58:70–76.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:6051–6060.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:709–717.
   PubMed Web of Science ®Google Scholar
• Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271–281.
   PubMed Web of Science ®Google Scholar
• Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607–1616.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2018;124:271–277.
   PubMed Web of Science ®Google Scholar
• Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50:1700050.
   PubMed Web of Science ®Google Scholar
• Guibert N, Delaunay M, Mazières J. Targeting the immune system to treat lung cancer: rationale and clinical experience. Ther Adv Respir Dis. 2015;9:105–120.
   PubMed Web of Science ®Google Scholar
• Kostine M, Rouxel L, Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis. 2018;77:393–398.
   PubMed Web of Science ®Google Scholar
• Le Burel S, Champiat S, Mateus C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur J Cancer Oxf Engl 1990. 2017;82:34–44.
   PubMed Web of Science ®Google Scholar
• Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747–1750.
   PubMed Web of Science ®Google Scholar
• Roger A, Groh M, Lorillon G, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. Ann Rheum Dis. 2018.
   PubMed Web of Science ®Google Scholar
• Danlos F-X, Voisin A-L, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer Oxf Engl 1990. 2018;91:21–29.
   PubMed Web of Science ®Google Scholar
• Albayda J, Bingham CO, Shah AA, et al. Metastatic joint involvement or inflammatory arthritis? A conundrum with immune checkpoint inhibitor-related adverse events. Rheumatol Oxf Engl. 2018;57:760–762.
   PubMed Web of Science ®Google Scholar
• Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017;69:1751–1763.
   PubMed Web of Science ®Google Scholar
• Touat M, Talmasov D, Ricard D, et al. Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol. 2017;30:659–668.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Eltobgy M, Oweira H, et al. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. Immunotherapy. 2017;9:1175–1183.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Abe R, Haga N, et al. A case of drug-associated dermatomyositis following ipilimumab therapy. Eur J Dermatol EJD. 2016;26:320–321.
   PubMed Web of Science ®Google Scholar
• Kudo F, Watanabe Y, Iwai Y, et al. A case of advanced lung adenocarcinoma with Nvolumab-associated dermatomyositis. Intern Med Tokyo Jpn. 2018.
   Google Scholar
• Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor–related myositis and myocarditis in patients with cancer. Neurology. Forthcoming.
   Web of Science ®Google Scholar
• Gallay L, Bourgeois-Vionnet J, Joubert B, et al. Muscular disorder related to immune checkpoint inhibitors: forewarned is forearmed. Neuro-Oncol. 2018;20:861–862.
   PubMed Web of Science ®Google Scholar
• Bilen MA, Subudhi SK, Gao J, et al. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. J Immunother Cancer. 2016;4:36.
   PubMed Web of Science ®Google Scholar
• Haddox CL, Shenoy N, Shah KK, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:673–675.
   PubMed Web of Science ®Google Scholar
• Pushkarevskaya A, Neuberger U, Dimitrakopoulou-Strauss A, et al. Severe ocular myositis after ipilimumab treatment for melanoma: a report of 2 cases. J Immunother Hagerstown Md 1997. 2017;40:282–285.
   Google Scholar
• Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89:1127–1134.
   PubMed Web of Science ®Google Scholar
• Chen J-H, Lee K-Y, Hu C-J, et al. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review. Medicine (Baltimore). 2017;96:e9262.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Ederhy S, Voisin A-L, Champiat S. Myocarditis with immune checkpoint blockade. N Engl J Med. 2017;376:290–291.
   PubMedGoogle Scholar
• Moslehi JJ, Salem J-E, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet Lond Engl. 2018;391:933.
   PubMed Web of Science ®Google Scholar
• Escudier M, Cautela J, Malissen N, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136:2085–2087.
   PubMed Web of Science ®Google Scholar
• Arangalage D, Delyon J, Lermuzeaux M, et al. Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med. 2017;167:683–684.
   PubMed Web of Science ®Google Scholar
• Matson DR, Accola MA, Rehrauer WM, et al. Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab. J Forensic Sci. 2018;63:954–957.
   PubMed Web of Science ®Google Scholar
• Semper H, Muehlberg F, Schulz-Menger J, et al. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Lung Cancer (Amst Neth). 2016;99:117–119.
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Keshino E, Makiyama A, et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail. 2016;9:e003514.
   PubMed Web of Science ®Google Scholar
• Frigeri M, Meyer P, Banfi C, et al. Immune checkpoint inhibitor-associated myocarditis: a new challenge for cardiologists. Can J Cardiol. 2018;34:92.e1–92.e3.
   PubMed Web of Science ®Google Scholar
• Geisler BP, Raad RA, Esaian D, et al. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J Immunother Cancer. 2015;3:4.
   PubMed Web of Science ®Google Scholar
• Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4:50.
   PubMed Web of Science ®Google Scholar
• Norwood TG, Westbrook BC, Johnson DB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5:91.
   PubMed Web of Science ®Google Scholar
• Reddy N, Moudgil R, Lopez-Mattei JC, et al. Progressive and reversible conduction disease with checkpoint inhibitors. Can J Cardiol. 2017;33:1335.e13–1335.e15.
   PubMed Web of Science ®Google Scholar
• Roth ME, Muluneh B, Jensen BC, et al. Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma. Am J Ther. 2016;23:e1925–e1928.
   PubMed Web of Science ®Google Scholar
• Yun S, Vincelette ND, Mansour I, et al. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842.
   PubMedGoogle Scholar
• Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer Oxf Engl 1990. 2016;60:210–225.
   PubMed Web of Science ®Google Scholar
• Ederhy S, Cautela J, Ancedy Y, et al. Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging. 2018;2517.
   Google Scholar
• Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–1764.
   PubMed Web of Science ®Google Scholar
• Neilan TG, Rothenberg ML, Amiri-Kordestani L, et al. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. 2018;23:874–878.
   Web of Science ®Google Scholar
• Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer Oxf Engl 1990. 2017;73:1–8.
   PubMed Web of Science ®Google Scholar
• Liao B, Shroff S, Kamiya-Matsuoka C, et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncol. 2014;16:589–593.
   PubMed Web of Science ®Google Scholar
• Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016;46:86–88.
   PubMed Web of Science ®Google Scholar
• Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107:1055–1058.
   PubMed Web of Science ®Google Scholar
• Maurice C, Schneider R, Kiehl T-R, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015;3:1299–1302.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016;86:1553–1556.
   PubMed Web of Science ®Google Scholar
• Khoja L, Maurice C, Chappell M, et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res. 2016;4:175–178.
   PubMed Web of Science ®Google Scholar
• Brown MP, Hissaria P, Hsieh AH, et al. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017;305:16–18.
   PubMed Web of Science ®Google Scholar
• Höftberger R, Rosenfeld MR, Dalmau J. Update on neurological paraneoplastic syndromes. Curr Opin Oncol. 2015;27:489–495.
   PubMed Web of Science ®Google Scholar
• Williams TJ, Benavides DR, Patrice K-A, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73:928–933.
   PubMed Web of Science ®Google Scholar
• Diamantopoulos PT, Tsatsou K, Benopoulou O, et al. Inflammatory myopathy and axonal neuropathy in a patient with melanoma following pembrolizumab treatment. J Immunother (Hagerstown Md 1997). 2017;40:221–223.
   PubMed Web of Science ®Google Scholar
• Bot I, Blank CU, Boogerd W, et al. Neurological immune-related adverse events of ipilimumab. Pract Neurol. 2013;13:278–280.
   PubMedGoogle Scholar